Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration

[1]  J. Vander.  A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Clinical and Economic Impact , 2011 .

[2]  C. Regillo,et al.  A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. , 2010, Ophthalmology.

[3]  C. Regillo,et al.  Management of Neovascular Age-Related Macular Degeneration Using Bevacizumab With the Treat and Extend Regimen: Clinical Results and Economic Impact , 2010 .

[4]  K. Freund,et al.  “TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION , 2009, Retina.

[5]  Sumit Sharma,et al.  Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. , 2009, Ophthalmology.

[6]  Philip J Rosenfeld,et al.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.

[7]  A. Saad,et al.  Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. , 2009, American journal of ophthalmology.

[8]  N. Eter,et al.  Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Interim Results From the Sustain Trial , 2008 .

[9]  A. Schakal,et al.  Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. , 2008, American journal of ophthalmology.

[10]  C. Regillo,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.

[11]  C. Regillo,et al.  Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. , 2007, American journal of ophthalmology.

[12]  R. Spaide.  Ranibizumab according to need: a treatment for age-related macular degeneration. , 2007, American journal of ophthalmology.

[13]  William J Feuer,et al.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[14]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[15]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[16]  D. Pauleikhoff,et al.  NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Natural History and Treatment Outcomes , 2005, Retina.

[17]  S. Resnikoff,et al.  Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.

[18]  B. Munoz,et al.  Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study. , 2004, Archives of ophthalmology.

[19]  P. Jong.  Prevalence of age-related macular degeneration in the United States. , 2004 .

[20]  A. Fletcher,et al.  Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study , 2004, Ophthalmic epidemiology.

[21]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[22]  Phillip G Yuile,et al.  Age‐related macular degeneration: a leading cause of blindness , 1997, The Medical journal of Australia.

[23]  F. Ferris,et al.  Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.